HUTCHISON CHINA/S (NASDAQ:HCM) has earned a consensus rating of “Buy” from the eight research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $27.91.
HCM has been the topic of a number of recent analyst reports. Bank of America initiated coverage on shares of HUTCHISON CHINA/S in a report on Wednesday, October 23rd. They set a “buy” rating and a $29.00 price target on the stock. CLSA initiated coverage on shares of HUTCHISON CHINA/S in a report on Tuesday, November 19th. They set a “buy” rating on the stock. Zacks Investment Research upgraded shares of HUTCHISON CHINA/S from a “sell” rating to a “hold” rating in a research report on Tuesday, October 22nd. Finally, BidaskClub upgraded shares of HUTCHISON CHINA/S from a “hold” rating to a “buy” rating in a research report on Tuesday, November 12th.
Institutional investors have recently modified their holdings of the stock. Invesco Ltd. purchased a new position in HUTCHISON CHINA/S during the second quarter worth about $81,486,000. Key Square Capital Management LLC acquired a new stake in HUTCHISON CHINA/S in the second quarter valued at approximately $24,263,000. Luminus Management LLC purchased a new position in HUTCHISON CHINA/S in the second quarter valued at approximately $13,200,000. Blackstone Group Inc purchased a new position in HUTCHISON CHINA/S in the second quarter valued at approximately $6,050,000. Finally, Prudential PLC grew its position in shares of HUTCHISON CHINA/S by 5.8% during the second quarter. Prudential PLC now owns 4,628,247 shares of the company’s stock worth $101,821,000 after acquiring an additional 254,151 shares during the last quarter. Institutional investors own 28.54% of the company’s stock.
HUTCHISON CHINA/S Company Profile
Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China and Hong Kong. The company operates through Innovation Platform and Commercial Platform segments.
Recommended Story: Gap Down Stocks
Receive News & Ratings for HUTCHISON CHINA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHISON CHINA/S and related companies with MarketBeat.com's FREE daily email newsletter.